Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study

Abstract

Background:

Alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis (MS) but requires ongoing pathology monitoring for autoimmune adverse effects. The Alemtuzumab in MS Safety Systems (AMS3) study evaluated the implementation of an automated pathology-monitoring system.

Objectives:

To develop an efficient automated clinical decision support system (CDSS) to electronically prompt and track pathology collection and to provide prescribers and patients with customised alerts of abnormal results for identified risks.

Methods:

A total of 10 patients with relapsing-remitting MS treated with alemtuzumab were enrolled to test the system. Standard care laboratory monitoring was performed and compared to the performance of the CDSS.

Results:

The automated CDSS, an integrated patient smartphone application and an additional pre-screening tool were all successfully developed. Compliance with pathology monitoring was 96.7%. The automated analysis of pathology results was significantly faster than standard care neurologist review (p < 0.001). The system correctly identified and alerted abnormalities, including one case of immune thrombocytopenia (ITP) while the treating neurologist was on leave, enabling prompt treatment of serious adverse events. During the course of the study, the CDSS was deployed throughout Australia.

Conclusion:

We successfully developed automated pathology monitoring with a CDSS, demonstrating real-world benefits of high compliance and timely alerting of important results.

Keywords

Alemtuzumab autoimmune automation clinical decision support system electronic monitoring immune thrombocytopenic purpura pathology monitoring smartphone

Get full access to this article

View all access options for this article.

References

Coles

Compston

Selmaj

et al . Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801.

Cohen

Coles

Arnold

et al . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380: 1819–1828.

Coles

Twyman

Arnold

et al . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380: 1829–1839.

Coles

Fox

Vladic

et al . Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78: 1069–1078.

Tuohy

Costelloe

Hill-Cawthorne

et al . Alemtuzumab treatment of multiple sclerosis: Long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015; 86: 208–215.

Dayan

Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS studies. In: Paper presentation at the ECTRIMS, London, 14th September 2016.

Reason

The contribution of latent human failures to the breakdown of complex systems. Philos Trans R Soc Lond B Biol Sci 1990; 327: 475–484.

Reason

Human error: Models and management. BMJ 2000; 320: 768–770.

Mori

Agarwal

Lee

MWM

et al . A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers. J Neuroimmunol 2017; 312: 4–7.

10.

Riminton

Hartung

Reddel

SW.

Managing the risks of immunosuppression. Curr Opin Neurol 2011; 24: 217–223.

11.

Cabana

Rand

Powe

et al . Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458–1465.

12.

Dean

Hart

Buchacz

et al . HIV laboratory monitoring reliably identifies persons engaged in care. J Acquir Immune Defic Syndr 2015; 68: 133–139.

13.

Shalom

Shahar

Parmet

et al . A multiple-scenario assessment of the effect of a continuous-care, guideline-based decision support system on clinicians’ compliance to clinical guidelines. Int J Med Inform 2015; 84: 248–262.

14.

Robbins

Lester

Johnson

et al . Efficacy of a clinical decision-support system in an HIV practice: A randomized trial. Ann Intern Med 2012; 157: 757–766.

15.

Zerillo

Goldenberg

Kotecha

et al . Interventions to improve oral chemotherapy safety and quality: A systematic review. JAMA Oncol 2018; 4: 105–117.